

NCT ID	NCT05608044
Title	A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer Without Liver Metastases
Phase	Phase 2
Date Added	2022-11-08
Location	Arizona, United States California, United States Colorado, United States Delaware, United States Florida, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Rhode Island, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Belgium Brazil France Georgia Italy Russian Federation Spain
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Balstilimab, Botensilimab, Regorafenib, TAS-102
Tags	MSS/ MMRp
NCT ID	NCT04895709
Title	A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors
Phase	Phase 1, Phase 2
Date Added	2021-05-20
Location	California, United States Iowa, United States New Jersey, United States New York, United States Oregon, United States Tennessee, United States Texas, United States Australia Canada Germany Israel Italy Japan Spain
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	BMS-936558-01, BMS-986340
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03400332
Title	A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Phase	Phase 2
Date Added	2018-01-17
Location	Arkansas, United States California, United States Colorado, United States Georgia, United States Maryland, United States Massachusetts, United States Michigan, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Texas, United States Utah, United States Virginia, United States Australia Belgium Canada France Germany Italy Poland Spain Sweden Switzerland United Kingdom
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	BMS-986253, Ipilimumab, Nivolumab
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT03289962
Title	A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Phase	Phase 1
Date Added	2017-09-21
Location	Arizona, United States California, United States Colorado, United States Connecticut, United States Massachusetts, United States Nevada, United States New York, United States Oklahoma, United States Oregon, United States Tennessee, United States Washington, United States Belgium Canada Germany Netherlands Spain Sweden United Kingdom
Prior IO Allowed	Yes
CRC-directed	Yes

Status	Active, not recruiting
Drugs	Atezolizumab, Autogene cevumeran, Tecentriq
Tags	MSS/ MMRp
NCT ID	NCT05684211
Title	A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer
Phase	Phase 2
Date Added	2023-01-13
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Not yet recruiting
Drugs	Ametumumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05167409
Title	A Study of ALX148 With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
Phase	Phase 2
Date Added	2021-12-22
Location	Arizona, United States Colorado, United States New Jersey, United States Virginia, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	ALX148, cetuximab, Evorpacept (ALX148), Pembrolizumab, Erbitux, Keytruda
Tags	MSS/ MMRp
NCT ID	NCT05382442
Title	A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
Phase	Phase 2
Date Added	2022-05-19
Location	California, United States China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	5-Fluorouracil, Bevacizumab, capecitabine, Irinotecan, Leucovorin, oxaliplatin
Tags	MSS/ MMRp
NCT ID	NCT02988960
Title	A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
Phase	Phase 1
Date Added	2016-12-12

Location	California, United States Illinois, United States Massachusetts, United States North Carolina, United States Tennessee, United States Texas, United States Virginia, United States Australia Canada France Japan Korea, Republic of Spain
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	ABBV-181, ABBV-927, Opdivo
Tags	MSS/ MMRp
NCT ID	NCT05141721
Title	A Study of a Personalized Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Phase	Phase 2
Date Added	2021-12-02
Location	Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Maryland, United States Michigan, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Wisconsin, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Atezolizumab, Bevacizumab, Fluoropyrimidine, GRT-C901, GRT-R902, Ipilimumab, oxaliplatin
Tags	MSS/ MMRp
NCT ID	VAPER
Title	A study looking at using a vaccine and chemotherapy to treat advanced cancer
Phase	Phase 1
Date Added	2015-11-17
Location	

Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Celecoxib, Cyclophosphamide, imiquimod, vaccine
Tags	MSS/ MMRp